Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Blood (2023) 142 (Supplement 1): 4962.

https://doi.org/10.1182/blood-2023-174479

Published: 2023

Journal Articles

Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy

Paolo Strati, Amanda Brandt, Jared Henderson, Jason Westin, Loretta J. Nastoupil, Ajlan Al Zaki, Andrew P Jallouk, Sherry Adkins, Elizabeth J. Shpall, Partow Kebriaei, Jeremy Ramdial, Neeraj Y. Saini, Sairah Ahmed, Christopher R. Flowers, Sattva S. Neelapu, Michelle Hildebrandt

Blood (2023) 142 (Supplement 1): 5139.

https://doi.org/10.1182/blood-2023-180744

Published: 2023

Journal Articles

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Qaiser Bashir, Marina Y. Konopleva, Glorette Abueg, Jeremy Ramdial, Chitra Hosing, Samer A. Srour, Amin Alousi, Uday R. Popat, Yago Nieto, Gheath Alatrash, Richard E. Champlin, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Naveen Pemmaraju

Blood (2023) 142 (Supplement 1): 7058.

https://doi.org/10.1182/blood-2023-178874

Published: 2023

Journal Articles

Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience

Blood (2023) 142 (Supplement 1): 6327.

https://doi.org/10.1182/blood-2023-191096

Published: 2023

Journal Articles

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2023-173040

Published: 2023

Journal Articles

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Blood (2023) 142 (Supplement 1): 233.

https://doi.org/10.1182/blood-2023-181880

Published: 2023

Journal Articles

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 3356.

https://doi.org/10.1182/blood-2023-174558

Published: 2023

Journal Articles

Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Blood (2023) 142 (Supplement 1): 4963.

https://doi.org/10.1182/blood-2023-173697

Published: 2023

Journal Articles

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Blood (2023) 142 (Supplement 1): 774.

https://doi.org/10.1182/blood-2023-172980

Published: 2023

Journal Articles

Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis

Alejandro Marinos Velarde, Rima M. Saliba, Celina Ledesma, Elizabeth J. Shpall, Muzaffar H. Qazilbash, Uday R. Popat, Qaiser Bashir, Yago Nieto, David Marin, Betul Oran, Amanda L. Olson, Samer A. Srour, Amin Alousi, Jeremy Ramdial, Partow Kebriaei, Alessandra Ferrajoli, William G. Wierda, Richard E. Champlin, Chitra Hosing

Blood (2023) 142 (Supplement 1): 7086.

https://doi.org/10.1182/blood-2023-173194

Published: 2023

Journal Articles

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Blood (2023) 142 (Supplement 1): 7070.

https://doi.org/10.1182/blood-2023-189109

Published: 2023

Journal Articles

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Andrew M. Evens, Alexey Danilov, Deepa Jagadeesh, Amy Sperling, Seo-Hyun Kim, Ryan Vaca, Catherine Wei, Daniel Rector, Suchitra Sundaram, Nishitha Reddy, Yong Lin, Umar Farooq, Christopher D'Angelo, David A. Bond, Stephanie Berg, Michael C. Churnetski, Amandeep Godara, Nadia Khan, Yun Kyong Choi, Maryam Yazdy, Emma Rabinovich, Gaurav Varma, Reem Karmali, Agrima Mian, Malvi Savani, Madelyn Burkart, Peter Martin, Albert Ren, Ayushi Chauhan, Catherine Diefenbach, Allandria Straker-Edwards, Andreas K. Klein, Kristie A. Blum, Kirsten Marie Boughan, Scott E. Smith, Brad M. Haverkos, Victor M. Orellana-Noia, Vaishalee P. Kenkre, Adam Zayac, Jeremy Ramdial, Seth M. Maliske, Narendranath Epperla, Parameswaran Venugopal, Tatyana A. Feldman, Stephen D. Smith, Andrzej Stadnik, Kevin A. David, Seema Naik, Izidore S. Lossos, Matthew A. Lunning, Paolo Caimi, Manali Kamdar, Neil Palmisiano, Veronika Bachanova, Craig A. Portell, Tycel Phillips, Adam J. Olszewski, Juan Pablo Alderuccio

Blood (2021) 137 (3): 374–386.

https://doi.org/10.1182/blood.2020006926

Published: 2021

Includes: Supplemental data

Journal Articles

Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance

Mahmoud R. Gaballa, MD, Taha Al-Juhaishi, MD, Qaiser Bashir, MD, Samer A. Srour, MD MS, Neeraj Saini, MD, Jeremy Ramdial, MD, Yago Nieto, MD, Regan Murphy, PA-C, Hans C. Lee, MD, Krina K. Patel, MD, Partow Kebriaei, MD, Sheeba K. Thomas, MD, Donna M. Weber, MD, Robert Z. Orlowski, MDPhD, Richard E. Champlin, MD, Muzaffar H. Qazilbash, MD

Blood (2020) 136 (Supplement 1): 14–15.

https://doi.org/10.1182/blood-2020-135865

Published: 2020

Journal Articles

The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-141388

Published: 2020

Journal Articles

Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-139880

Published: 2020

Journal Articles

High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC)

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-134471

Published: 2020

Journal Articles

Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation

Blood (2019) 134 (Supplement_1): 512.

https://doi.org/10.1182/blood-2019-125937

Published: 2019

Journal Articles

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Andrew M. Evens, DO, MSc, Alexey Danilov, MD PhD, Deepa Jagadeesh, MDMPH, Amy Sperling, BS, Seo-Hyun Kim, MD, Ryan Vaca, MD, Catherine Wei, MD MA, Daniel Rector, Suchitra Sundaram, MD, Nishitha Reddy, MD, Yong Lin, PhD, Umar Farooq, MD, Christopher D'Angelo, MD, David A. Bond, MD, Stephanie Berg, DO, Michael C. Churnetski, Amandeep Godara, MD, Nadia Khan, MD, Yun Kyong Choi, MD, Maryam Yazdy, MD, Emma Rabinovich, MD, Gaurav Varma, MD MSPH, Reem Karmali, MD, Agrima Mian, MBBS, MD, Jeremy Ramdial, MD, Madelyn Burkart, MD, Peter Martin, FRCPC, MD MS, Albert Ren, Ayushi Chauhan, MBBS, Catherine Diefenbach, MD, Allandria Straker-Edwards, MS, Andreas Klein, MD, Kristie A. Blum, MD, Kirsten M Boughan, DO, Scott E. Smith, MD PhD, Brad M. Haverkos, MDMPH,MS, Victor M. Orellana-Noia, MD, Vaishalee P. Kenkre, MD, Adam Zayac, MD, Seth M Maliske, MD, Narendranath Epperla, MDMS, Parameswaran Venugopal, MD, Tatyana A. Feldman, MD, Stephen D. Smith, MD, Andrzej Stadnik, MPH, BS, Izidore S. Lossos, MD, Kevin A. David, MD, Seema Naik, MD, Paolo Caimi, MD, Manali Kamdar, MD, Craig A. Portell, MD, Adam J Olszewski, MD, Juan Pablo Alderuccio, MD

Blood (2019) 134 (Supplement_1): 397.

https://doi.org/10.1182/blood-2019-122971

Published: 2019

Journal Articles

Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma

Marco Magistri, PhD MS, Lanie Happ, Jeremy Ramdial, MD, Kranthi Kunkalla, Sander R Dubovy, MD, Jennifer R Chapman, MD, Francisco Vega, MD PhD, Sandeep Dave, MD, Izidore S. Lossos, MD

Blood (2018) 132 (Supplement 1): 923.

https://doi.org/10.1182/blood-2018-99-111325

Published: 2018

NARROW

Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center

Germline Determinants of Toxicity and Efficacy in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 Autologous CAR T-Cell Therapy

Tagraxofusp Maintenance Post-Hematopoietic Stem Cell Transplantation Provides Long-Term Survival and Manageable Safety for a Patient with Blastic Plasmacytoid Dendritic Cell Neoplasm

Outcomes in Patients with Relapsed Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with CAR-T Cell Therapies or Salvage Chemotherapy - a Single-Institution Experience

Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation

Addition of Inotuzumab Ozogamicin to the Conditioning Regimen of Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed CD22 (+) Lymphoid Malignancies: Long-Term Survival Results

Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation

Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience

Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results

Allogeneic Transplant for CLL Richter's Transformation: Single Center Retrospective Analysis

Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation

Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers

Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance

The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL)

Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience

High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC)

Somatic Mutations Improve Risk Classification By Cytogenetic Abnormalities in Patients with Myelodysplastic Syndrome after Hematopoietic Stem Cell Transplantation

The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)

Genetic Landscape of Ocular Adnexa Extranodal Marginal Zone Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only